Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches

Bibliography

• THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113(6):e85-e151.
   PubMed Web of Science ®Google Scholar
• JACOBSEN BK, KNUTSEN SF, FRASER GE: Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J. Clin. Epidemiol. (1999) 52(4):303-307.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN ME: Protective effects of estrogen on the cardiovascular system. Am. J. Cardiol. (2002) 89(12A):12E-17E; discussion 17E-18E.
   Web of Science ®Google Scholar
• KALANTARIDOU SN, NAKA KK, BECHLIOULIS A et al.: Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol. Metab. (2006) 17(3):101-109.
   PubMed Web of Science ®Google Scholar
• VIRDIS A, GHIADONI L, PINTO S et al.: Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation (2000) 101(19):2258-2263.
   PubMed Web of Science ®Google Scholar
• SENOZ S, DIREM B, GULEKLI B, GOKMEN O: Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women. Maturitas (1996) 25(2):107-114.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, WILLETT WC, COLDITZ GA et al.: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N. Engl. J. Med. (1985) 313(17):1044-1049.
   PubMed Web of Science ®Google Scholar
• FEINLEIB M: Discussion of: ‘Epidemiology of cardiovascular diseases: current perspectives’. Am. J. Epidemiol. (1976) 104(4):457-462.
   PubMedGoogle Scholar
• GRODSTEIN F, MANSON JE, STAMPFER MJ: Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt) (2006) 15(1):35-44.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, COLDITZ GA, WILLETT WC et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N. Engl. J. Med. (1991) 325(11):756-762.
   PubMed Web of Science ®Google Scholar
• HERRINGTON DM, KLEIN KP: Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis (2003) 166(2):203-212.
   PubMed Web of Science ®Google Scholar
• HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280(7):605-613.
   PubMed Web of Science ®Google Scholar
• GRADY D, HERRINGTON D, BITTNER V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 288(1):49-57.
   PubMed Web of Science ®Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
   PubMed Web of Science ®Google Scholar
• STEINBERG KK, THACKER SB, SMITH SJ et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA (1991) 265(15):1985-1990.
   PubMed Web of Science ®Google Scholar
• ANDERSON GL, LIMACHER M, ASSAF AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA (2004) 291(14):1701-1712.
   PubMed Web of Science ®Google Scholar
• MOSCA L, APPEL LJ, BENJAMIN EJ et al.: Summary of the American Heart Association’s evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler. Thromb. Vasc. Biol. (2004) 24(3):394-396.
   PubMed Web of Science ®Google Scholar
• GRIMES DA, LOBO RA: Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet. Gynecol. (2002) 100(6):1344-1353.
   PubMed Web of Science ®Google Scholar
• OUYANG P, MICHOS ED, KARAS RH: Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J. Am. Coll. Cardiol. (2006) 47(9):1741-1753.
   PubMed Web of Science ®Google Scholar
• SALPETER S: Mortality associated with hormone replacement therapy in younger and older women. J. Gen. Intern. Med. (2006) 21(4):401.
   PubMedGoogle Scholar
• MANSON JE, BASSUK SS, HARMAN SM et al.: Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause (2006) 13(1):139-147.
   PubMed Web of Science ®Google Scholar
• SEALS DR, MOREAU KL, GATES PE, ESKURZA I: Modulatory influences on ageing of the vasculature in healthy humans. Exp. Gerontol. (2006) 41(5):501-507.
   PubMedGoogle Scholar
• LOSORDO DW, KEARNEY M, KIM EA, JEKANOWSKI J, ISNER JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation (1994) 89(4):1501-1510.
   PubMed Web of Science ®Google Scholar
• POST WS, GOLDSCHMIDT-CLERMONT PJ, WILHIDE CC et al.: Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc. Res. (1999) 43(4):985-991.
   PubMed Web of Science ®Google Scholar
• KARAS R, CLARKSON D: Considerations in interpreting the cardiovascular effects of homone-replacement therapy observed in the WHI: timing is everything. Menopausal Medicine (2003) 10:8-12.
   Google Scholar
• ZANGER D, YANG BK, ARDANS J et al.: Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol. (2000) 36(6):1797-1802.
   PubMed Web of Science ®Google Scholar
• STEVENSON JC: The metabolic basis for the effects of HRT on coronary heart disease. Endocrine (2004) 24(3):239-244.
   PubMed Web of Science ®Google Scholar
• STURDEE DW: Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int. J. Clin. Pract. (1999) 53(6):468-472.
   PubMedGoogle Scholar
• POST MS, CHRISTELLA M, THOMASSEN LG et al.: Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. (2003) 23(6):1116-1121.
   PubMed Web of Science ®Google Scholar
• LAKOSKI SG, HERRINGTON DM: Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric (2005) 8(4):317-326.
   PubMed Web of Science ®Google Scholar
• BLUMEL JE, CASTELO-BRANCO C, LEAL T et al.: Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric (2003) 6(1):38-44.
   PubMed Web of Science ®Google Scholar
• SIMONCINI T, MANNELLA P, FORNARI L et al.: In vitro effects of progesterone and progestins on vascular cells. Steroids (2003) 68(10-13):831-836.
   PubMed Web of Science ®Google Scholar
• OISHI A, OHMICHI M, TAKAHASHI K et al.: Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. (2004) 324(1):193-198.
   PubMed Web of Science ®Google Scholar
• WAKATSUKI A, OKATANI Y, IKENOUE N, FUKAYA T: Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation (2001) 104(15):1773-1778.
   PubMed Web of Science ®Google Scholar
• LEVINE RL, CHEN SJ, DURAND J, CHEN YF, OPARIL S: Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation (1996) 94(9):2221-2227.
   PubMed Web of Science ®Google Scholar
• JEANES HL, WANIKIAT P, SHARIF I, GRAY GA: Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause (2006) 13(1):80-86.
   PubMed Web of Science ®Google Scholar
• HSIA J, LANGER RD, MANSON JE et al.: Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch. Intern. Med. (2006) 166(3):357-365.
   PubMed Web of Science ®Google Scholar
• MEIJER R, GROBEE DE, BOTS ML: Mannheim consensus on carotid intima-media thickness: opposite and complementary points of view. Cerebrovasc. Dis. (2006) 21(5-6):415-416.
   PubMedGoogle Scholar
• DEVINE PJ, CARLSON DW, TAYLOR AJ: Clinical value of carotid intima-media thickness testing. J. Nucl. Cardiol. (2006) 13(5):710-718.
   PubMed Web of Science ®Google Scholar
• TOUBOUL PJ, HENNERICI MG, MEAIRS S et al.: Mannheim intima-media thickness consensus. Cerebrovasc. Dis. (2004) 18(4):346-349.
   PubMed Web of Science ®Google Scholar
• DEMISSIE S, CUPPLES LA, SHEARMAN AM et al.: Estrogen receptor-α variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. Atherosclerosis (2006) 185(1):210-218.
   PubMed Web of Science ®Google Scholar
• LEIBOWITZ D, DRESNER-POLLAK R, DVIR S et al.: Association of an estrogen receptor-α gene polymorphism with left ventricular mass. Blood Press. (2006) 15(1):45-50.
   PubMed Web of Science ®Google Scholar
• HOETZER GL, IRMIGER HM, STAUFFER BL, DESOUZA CA: Estrogen receptor-α thymidine and adenine repeat polymorphism and endothelial fibrinolytic regulation in postmenopausal women. Am. J. Obstet. Gynecol. (2005) 193(2):366-370.
   PubMedGoogle Scholar
• EMRE A, SAHIN S, ERZIK C et al.: Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C Genotype and Established Coronary Artery Disease. Cardiology (2006) 106(1):44-50.
   PubMed Web of Science ®Google Scholar
• HERRINGTON DM, HOWARD TD, BROSNIHAN KB et al.: Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation (2002) 105(16):1879-1882.
   PubMed Web of Science ®Google Scholar
• ALMEIDA S, FRANKEN N, ZANDONA MR, OSORIO-WENDER MC, HUTZ MH: Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J. (2005) 5(1):30-34.
   PubMed Web of Science ®Google Scholar
• GRAY GA, SHARIF I, WEBB DJ, SECKL JR: Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends Pharmacol. Sci. (2001) 22(3):152-156.
   PubMedGoogle Scholar
• MENDELSOHN ME: Mechanisms of estrogen action in the cardiovascular system. J. Steroid Biochem. Mol. Biol. (2000) 74(5):337-343.
   PubMed Web of Science ®Google Scholar
• SIMONCINI T, HAFEZI-MOGHADAM A, BRAZIL DP et al.: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (2000) 407(6803):538-541.
   PubMed Web of Science ®Google Scholar
• LU Q, PALLAS DC, SURKS HK et al.: Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. USA (2004) 101(49):17126-17131.
   PubMed Web of Science ®Google Scholar
• POTIER M, ELLIOT SJ, TACK I et al.: Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. (2001) 12(2):241-251.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON JA: Estrogen receptor β-a new dimension in estrogen mechanism of action. J. Endocrinol. (1999) 163(3):379-383.
   PubMed Web of Science ®Google Scholar
• BOLEGO C, CIGNARELLA A, SANVITO P et al.: The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J. Pharmacol. Exp. Ther. (2005) 313(3):1203-1208.
   PubMed Web of Science ®Google Scholar
• BOOTH EA, OBEID NR, LUCCHESI BR: Activation of estrogen receptor-α protects the in vivo rabbit heart from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. (2005) 289(5):H2039-2047.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI M, RACHELSKA G, DONGHAO W, MCCANN SM, GUTKOWSKA J: Estrogen receptors activate atrial natriuretic peptide in the rat heart. Pro.c Natl. Acad. Sci. USA (2001) 98(20):11765-11770.
   PubMed Web of Science ®Google Scholar
• WANG M, CRISOSTOMO P, WAIRIUKO GM, MELDRUM DR: Estrogen receptor-alpha mediates acute myocardial protection in females. Am. J. Physiol. Heart Circ. Physiol. (2006) 290(6):H2204-2209.
   PubMed Web of Science ®Google Scholar
• KORTE T, FUCHS M, ARKUDAS A et al.: Female mice lacking estrogen receptor beta display prolonged ventricular repolarization and reduced ventricular automaticity after myocardial infarction. Circulation (2005) 111(18):2282-2290.
   PubMedGoogle Scholar
• GABEL SA, WALKER VR, LONDON RE et al.: Estrogen receptor β mediates gender differences in ischemia/reperfusion injury. J. Mol. Cell. Cardiol. (2005) 38(2):289-297.
   PubMedGoogle Scholar
• BARRETT-CONNOR E, STUENKEL C: Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. J. Clin. Endocrinol. Metab. (1999) 84(6):1848-1853.
   Google Scholar
• ADAMS MR, REGISTER TC, GOLDEN DL, WAGNER JD, WILLIAMS JK: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17(1):217-221.
   PubMed Web of Science ®Google Scholar
• MOSCA L, BARRETT-CONNOR E, WENGER NK et al.: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. (2001) 88(4):392-395.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, MOSCA L, COLLINS P et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. (2006) 355(2):125-137.
   PubMedGoogle Scholar
• WENGER NK, BARRETT-CONNOR E, COLLINS P et al.: Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am. J. Cardiol. (2002) 90(11):1204-1210.
   PubMed Web of Science ®Google Scholar
• BLUMENTHAL RS, BARANOWSKI B, DOWSETT SA: Cardiovascular effects of raloxifene: the arterial and venous systems. Am. Heart J. (2004) 147(5):783-789.
   PubMed Web of Science ®Google Scholar
• SOMUNKIRAN A, YAZICI B, DEMIRCI F, ERDOGMUS B, OZDEMIR I: Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause. Climacteric (2006) 9(1):59-65.
   PubMed Web of Science ®Google Scholar
• QUYYUMI AA: Women and ischemic heart disease: pathophysiologic implications from the Women’s Ischemia Syndrome Evaluation (WISE) Study and future research steps. J. Am. Coll. Cardiol. (2006) 47(3 Suppl.):S66-S71.
   Google Scholar
• VIRMANI R, BURKE AP, FARB A, KOLODGIE FD: Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. (2006) 47(8 Suppl.):C13-18.
   PubMed Web of Science ®Google Scholar
• BURKE AP, FARB A, MALCOM GT et al.: Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation (1998) 97(21):2110-2116.
   PubMed Web of Science ®Google Scholar
• SIMON T, MARY-KRAUSE M, CAMBOU JP et al.: Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women: results from the French nation-wide USIC registries. Eur. Heart J. (2006) 27(11):1282-1288.
   PubMed Web of Science ®Google Scholar
• VACCARINO V, PARSONS L, EVERY NR, BARRON HV, KRUMHOLZ HM: Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N. Engl. J. Med. (1999) 341(4):217-225.
   PubMed Web of Science ®Google Scholar
• VACCARINO V, KRUMHOLZ HM, YARZEBSKI J, GORE JM, GOLDBERG RJ: Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann. Intern. Med. (2001) 134(3):173-181.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, SOLOMON S, PIEPER K et al.: The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol. (2006) 47(4):726-733.
   PubMed Web of Science ®Google Scholar
• MEHTA PA, COWIE MR: Gender and heart failure: a population perspective. Heart (2006) 92 (Suppl. 3):iii14-iii18.
   PubMedGoogle Scholar
• PETRIE MC, DAWSON NF, MURDOCH DR, DAVIE AP, MCMURRAY JJ: Failure of women’s hearts. Circulation (1999) 99(17):2334-2341.
   PubMed Web of Science ®Google Scholar
• ARGULIAN E, PATEL AD, ABRAMSON JL et al.: Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. Am. J. Cardiol. (2006) 98(1):48-53.
   PubMedGoogle Scholar
• LANSKY AJ, MEHRAN R, DANGAS G et al.: Comparison of differences in outcome after percutaneous coronary intervention in men versus women < 40 years of age. Am. J. Cardiol. (2004) 93(7):916-919.
   PubMedGoogle Scholar
• BAO T, PROWELL T, STEARNS V: Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am. J. Ther. (2006) 13(4):337-348.
   PubMedGoogle Scholar